Results 1 to 10 of about 519,396 (228)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database

Chinese Medical Journal, 2021
. Background:. Taxanes are an essential class of antineoplastic agents used to treat various cancers and are a fundamental cause of hypersensitivity reactions. In addition, other adverse events, such as bone marrow toxicity and peripheral neuropathy, can
Dong-Hui Lao, Ye Chen, Jun Fan, Jian-Zhong Zhang, Peng Lyu.   +4 more
doaj   +3 more sources

Adverse event reporting of mirtazapine: A disproportionality analysis of FDA adverse event reporting system (FAERS) database from 2004-2024. [PDF]

PLoS ONE
BackgroundMirtazapine is a pharmacological agent commonly utilized as a first-line treatment for major depressive disorder, exhibiting both noradrenergic and selective serotonergic activity.
Keying Guo, Haipeng Li, Wei Wang, Ling Cheng, Weina Du, Jing Zhang   +5 more
doaj   +2 more sources

Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system [PDF]

Frontiers in Neurology
BackgroundAlzheimer’s disease (AD) has a growing global prevalence, and the need for safe and effective treatments is urgent. Donepezil is commonly used therapeutic agents for AD but has safety controversies. The objective of this study was to thoroughly
Shuo Li, Wenlong Qian, Zhuo Zhang, Yonghua Chen, Yonghua Chen, Yonghua Chen, Xiaoxiao Hou, Bingjie Min, Hui Zhou, Xinyu Zhu, Jia Ling, Wenming Yang, Wenming Yang, Wenming Yang, Shijian Cao, Shijian Cao, Shijian Cao   +16 more
doaj   +2 more sources

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
BackgroundFaricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs ...
Chang-Zhu He, Qin Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He   +5 more
doaj   +3 more sources

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod [PDF]

Frontiers in Pharmacology
ObjectiveTo characterize the post-marketing safety profile of etrasimod using the latest data from the FDA Adverse Event Reporting System (FAERS), and to provide a comparative analysis versus other sphingosine-1-phosphate (S1P) receptor modulators ...
Yingxiu Wu, Yingxiu Wu, Wei Ke, Wei Ke, Huibiao Li   +4 more
doaj   +2 more sources

Vonoprazan-related adverse events: a pharmacovigilance study based on the FDA adverse event reporting system [PDF]

Frontiers in Medicine
This study comprehensively evaluated the safety profile of Vonoprazan using data from the FDA Adverse Event Reporting System (FAERS) from the first quarter (Q1) of 2023 through the first quarter (Q1) of 2025.
Yali Zhong, Cong Hou, Jie Zhang, Jie Zhang, Li Wang, Dongmei Xiong, Huang Zhong, Xiaobin Luo, Xiaobin Luo, Xiaobin Luo   +9 more
doaj   +2 more sources

Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system [PDF]

PLoS ONE
BackgroundGlofitamab offers a promising option for the treatment of diffuse large B-cell lymphoma. It is crucial to gather comprehensive safety information of glofitamab through large-scale post market monitoring.MethodsThis study conducted a ...
Meng Zhou, Cheng Jiang, Chuanyong Su
doaj   +3 more sources

Adverse events associated with cyclophosphamide: A pharmacovigilance study using the FDA adverse event reporting system [PDF]

PLoS ONE
ObjectiveCyclophosphamide(CHOP) is a widely used chemotherapeutic agent belonging to the class of alkylating agents. It primarily inhibits the proliferation of tumor cells by interfering with DNA replication and transcription.
Hui Zhang, Minghao Lin, Dexi Zhao, Yujuan Fu   +3 more
doaj   +3 more sources

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study

Heliyon
Background: Alpelisib was approved for treatment of breast cancer. We assessed the safety signals associated with alpelisib by data mining the FDA pharmacovigilance database. Methods: Data from the second quarter of 2019 to the fourth quarter of 2022 had
Yun Li, Hang Li, Zhongyuan Xiang
doaj   +3 more sources

Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system

Frontiers in Public Health
IntroductionHepatitis B virus (HBV) is a major cause of chronic liver disease. While the hepatitis B vaccine has been proven effective in preventing HBV infection, concerns regarding Events Supposedly Attributable to Vaccination or Immunization (ESAVI ...
Yiqing Sun, Bukun Zhu, Xiang Li, Zhanyang Luo, Weiguo Bian   +4 more
doaj   +3 more sources